The main board of the Hong Kong stock exchange of Ruike biological delivery, a vaccine company, focuses on the research and development of HPV candidate vaccines

According to the documents of the Hong Kong stock exchange, Jiangsu Ruike Biotechnology Co., Ltd. submitted a listing application to the Hong Kong stock exchange. Morgan Stanley, China Merchants Bank International and Citic Securities Company Limited(600030) are the co sponsors. The company mainly focuses on the research and development of HPV candidate vaccines, and has established a vaccine combination composed of 12 candidate vaccines, including the core product rec603, a recombinant HPV nine valent vaccine for the prevention of cervical cancer, which is currently in the phase III clinical trial stage. The company is also developing two covid-19 pneumonia vaccines, recov and r520a. In addition, the company currently has no products approved for commercial sales, nor does it generate any revenue from vaccine sales. For the years ended December 31, 2019 and 2020 and the nine months ended September 30, 2021, the total comprehensive losses of the company were RMB 138.3 million, RMB 179.4 million and RMB 520.4 million respectively.